Everolimus has 31 known drug interactions based on U.S. FDA drug labeling data. Of these, 12 are contraindicated combinations that should be avoided entirely. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Boceprevir, Clarithromycin, Itraconazole. Patients taking Everolimus should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 31
- Contraindicated
- 12
- Major
- 6
- Moderate
- 8
Contraindicated (12)
- Everolimus + Boceprevir— Strong CYP3A4 inhibitor. Should not be coadministered with everolimus.
- Everolimus + Clarithromycin— Strong CYP3A4 inhibitor. Should not be coadministered with everolimus.
- Everolimus + Itraconazole— Strong CYP3A4 inhibitor. Should not be coadministered with everolimus.
- Everolimus + Ketoconazole— Strong CYP3A4 inhibitor that significantly increases everolimus Cmax, AUC, and half-life. Should not be coadministered.
- Everolimus + Mao Inhibitors— Concomitant use may increase risk of angioedema. Avoid concomitant use.
- Everolimus + Rifabutin— Strong CYP3A4 inducer. Should not be coadministered with everolimus.
- Everolimus + Rifampin— Strong CYP3A4 inducer. Concurrent treatment is not recommended as it may decrease everolimus concentrations.
- Everolimus + Ritonavir— Strong CYP3A4 inhibitor. Should not be coadministered with everolimus.
- Everolimus + Strong Cyp3a4 And P-Glycoprotein Inducers— Avoid concomitant use of P-gp and strong CYP3A4 inhibitors with everolimus due to increased drug exposure.
- Everolimus + Telaprevir— Strong CYP3A4 inhibitor. Should not be coadministered with everolimus.
- Everolimus + Telithromycin— Strong CYP3A4 inhibitor. Should not be coadministered with everolimus.
- Everolimus + Voriconazole— Strong CYP3A4 inhibitor. Should not be coadministered with everolimus.
Major (6)
- Everolimus + Benazepril Hydrochloride And Hydrochlorothiazide— mTOR inhibitor coadministration with ACE inhibitor may increase risk for angioedema.
- Everolimus + Cannabidiol— Therapeutic drug monitoring and dose reduction for everolimus should be considered when coadministered.
- Everolimus + Cyclosporine— Significantly increases everolimus Cmax and AUC. Dose adjustment of everolimus may be needed if cyclosporine dose is alt…
- Everolimus + Digoxin— P-glycoprotein inhibitor that may decrease efflux of everolimus from intestinal cells and increase everolimus blood conc…
- Everolimus + Erythromycin— Moderate CYP3A4 inhibitor that significantly increases everolimus Cmax and AUC. Consider dose adjustment.
- Everolimus + Verapamil— CYP3A4 inhibitor may affect everolimus concentrations; dose adjustment consideration recommended.
Moderate (8)
- Everolimus + Amprenavir— 7.10 Other Possible Interactions Moderate inhibitors of CYP3A4 and P-gp may increase everolimus blood concentrations (e.…
- Everolimus + Benazepril Hydrochloride— mTOR inhibitor; coadministration with ACE inhibitors requires monitoring.
- Everolimus + Deferasirox— Deferasirox may induce CYP3A4 resulting in decreased everolimus concentration. Monitor for reduced effectiveness.
- Everolimus + Fluconazole— 7.10 Other Possible Interactions Moderate inhibitors of CYP3A4 and P-gp may increase everolimus blood concentrations (e.…
- Everolimus + Indinavir— 7.10 Other Possible Interactions Moderate inhibitors of CYP3A4 and P-gp may increase everolimus blood concentrations (e.…
- Everolimus + Nelfinavir— 7.10 Other Possible Interactions Moderate inhibitors of CYP3A4 and P-gp may increase everolimus blood concentrations (e.…
- Everolimus + Nicardipine— 7.10 Other Possible Interactions Moderate inhibitors of CYP3A4 and P-gp may increase everolimus blood concentrations (e.…
- Everolimus + Palbociclib— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.